Synthesis of novel isoflavene derivatives with anti-tumour activity

A novel series of isoflavonoid derivatives were generated through click chemistry modifications of the biologically active isoflavene phenoxodiol (PXD). PXD is an effective anticancer and anti-inflammatory agent with estrogen modulating properties which has been evaluated in phase II and III clinical trials. This novel series of analogues was designed to improve PDX's potency and selectivity against estrogen-positive cancers. Although the resulting compounds demonstrated poor estrogen receptor binding affinity, in vitro evaluation nonetheless yielded hit compounds with a 19-fold improvement in anticancer activity compared to PXD (IC₅₀ = 1.5 μM in T-47-D), along with an understanding of the underlying structure activity relationships (SAR).